One such change, often less spoken about, is the enlargement of the prostate gland. This condition, known as Benign Prostatic Hyperplasia (BPH), is extremely common, especially in men above 50 years ...

Results with Optilume consistent in clinical trials and real world, regardless of prostate ...

EDAP management highlighted what it sees as a growing global opportunity for therapeutic ultrasound in urology, emphasizing the company’s Focal One robotic high-intensity focused ultrasound (HIFU) ...

As a potential biomarker of treatment response, ctDNA and utDNA analyses were performed before systemic therapy, at restaging, and for responders at the beginning of adjuvant nivolumab. ctDNA was ...

Two former employees at Chesapeake Regional Medical Center are speaking out against the hospital, claiming they told ...

The earliest indicator of bladder cancer is the presence of blood in the urine. At later stages, the illness may be accompanied by pain in the flank, pelvis, and weight loss ...

Relmada Therapeutics (NASDAQ:RLMD) outlined progress on its lead urology oncology program and reviewed fourth-quarter results during its fourth quarter and full year 2025 earnings call, highlighting ...

ASX healthcare stocks remain under pressure, but strong clinical and regulatory catalysts are still driving standout gains across the sector. ... Read More The post Scott Power: Conflict, inflation ...

Shenouda With me on today's call are Relmada Therapeutics, Inc.'s CEO, Dr. Sergio Traversa, who will briefly provide a summary of recent business highlights; Dr. Raj S. Pruthi, Relmada Therapeutics, ...

Bellmunt Risk Score predicts survival in mCRPC across treatment lines. Learn how this simple tool can guide prognosis and treatment decisions. Read more.

Fueled by the manosphere, men are boosting their testosterone levels through natural and synthetic means, with some ...

The National Medical Commission (NMC) has laid down the bed strength and faculty requirements for postgraduate seats in ...